HK1208822A1 - Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders hpv/cyaa hpv hpv - Google Patents

Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders hpv/cyaa hpv hpv

Info

Publication number
HK1208822A1
HK1208822A1 HK15109607.9A HK15109607A HK1208822A1 HK 1208822 A1 HK1208822 A1 HK 1208822A1 HK 15109607 A HK15109607 A HK 15109607A HK 1208822 A1 HK1208822 A1 HK 1208822A1
Authority
HK
Hong Kong
Prior art keywords
hpv
cyaa
induction
immune responses
infection
Prior art date
Application number
HK15109607.9A
Other languages
English (en)
Chinese (zh)
Inventor
Yolande Misseri
Philippe Bridonneau
Anne Goubier
Original Assignee
Genticel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genticel filed Critical Genticel
Publication of HK1208822A1 publication Critical patent/HK1208822A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15109607.9A 2012-07-23 2015-09-30 Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders hpv/cyaa hpv hpv HK1208822A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305898.4A EP2689786A1 (de) 2012-07-23 2012-07-23 HPV/CYAA-basierte chimäre Proteine und deren Verwendungen bei der Induktion von Immunreaktionen gegen eine HPV-Infektion und HPV-induzierter Störungen
PCT/EP2013/065549 WO2014016312A1 (en) 2012-07-23 2013-07-23 Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders

Publications (1)

Publication Number Publication Date
HK1208822A1 true HK1208822A1 (en) 2016-03-18

Family

ID=48832935

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109607.9A HK1208822A1 (en) 2012-07-23 2015-09-30 Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders hpv/cyaa hpv hpv

Country Status (21)

Country Link
US (1) US9827302B2 (de)
EP (2) EP2689786A1 (de)
JP (1) JP6466328B2 (de)
KR (1) KR20150031487A (de)
CN (1) CN104736173B (de)
AU (1) AU2013295047B2 (de)
CA (1) CA2879999A1 (de)
DK (1) DK2874657T3 (de)
ES (1) ES2712647T3 (de)
HK (1) HK1208822A1 (de)
HR (1) HRP20190108T1 (de)
HU (1) HUE042808T2 (de)
LT (1) LT2874657T (de)
MX (1) MX2015001021A (de)
PL (1) PL2874657T3 (de)
PT (1) PT2874657T (de)
RS (1) RS58313B1 (de)
RU (1) RU2015100212A (de)
SI (1) SI2874657T1 (de)
TR (1) TR201900695T4 (de)
WO (1) WO2014016312A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690172A1 (de) * 2012-07-23 2014-01-29 Genticel CYAA-basierte chimäre Proteine mit einem heterologen Polypeptid und deren Verwendungen bei der Induktion von Immunreaktionen
EP3037103A1 (de) * 2014-12-23 2016-06-29 Genticel Immunotherapeutischer Impfstoff mit E7-Proteinen von HPV16 und HPV18 fusioniert mit CyaA zur Verwendung bei mit HIV infizierten Personen
EP3323424A1 (de) * 2016-11-17 2018-05-23 Cyanimal IP Cyaa-polypeptide als immunomodulatorenverstärker
US20210220462A1 (en) * 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01209817A (ja) 1988-02-17 1989-08-23 Yamaha Corp 浮動少数点形ディジタル・アナログ変換器
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
EP1489092A1 (de) 2003-06-18 2004-12-22 Institut Pasteur Modifizierte Bordetella Adenylatcyclase mit oder ohne CD11b/CD18 Interaktionsdomäne und seine Verwendungen
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
WO2010011607A1 (en) 2008-07-22 2010-01-28 Promega Corporation Adp detection based luminescent phosphotransferase or atp hydrolase assay
EP2478915A1 (de) * 2011-01-24 2012-07-25 Genticel cyaA-getragene Polypeptid(e) und Verwendung zur Induzierung von therapeutischen und prophylaktischen Immunantworten

Also Published As

Publication number Publication date
MX2015001021A (es) 2015-08-05
JP6466328B2 (ja) 2019-02-13
CA2879999A1 (en) 2014-01-30
DK2874657T3 (en) 2019-02-11
PL2874657T3 (pl) 2019-05-31
CN104736173A (zh) 2015-06-24
US9827302B2 (en) 2017-11-28
EP2874657A1 (de) 2015-05-27
PT2874657T (pt) 2019-02-18
HRP20190108T1 (hr) 2019-03-22
AU2013295047A1 (en) 2015-02-05
ES2712647T3 (es) 2019-05-14
EP2874657B1 (de) 2018-10-17
CN104736173B (zh) 2019-02-05
HUE042808T2 (hu) 2019-07-29
EP2689786A1 (de) 2014-01-29
WO2014016312A1 (en) 2014-01-30
KR20150031487A (ko) 2015-03-24
SI2874657T1 (sl) 2019-03-29
TR201900695T4 (tr) 2019-03-21
RU2015100212A (ru) 2016-09-10
AU2013295047B2 (en) 2018-02-22
US20150250867A1 (en) 2015-09-10
RS58313B1 (sr) 2019-03-29
LT2874657T (lt) 2019-02-25
JP2015524420A (ja) 2015-08-24

Similar Documents

Publication Publication Date Title
HK1211607A1 (en) Chimeric fibroblast growth factor 21 proteins and methods of use 21
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
HK1206370A1 (en) Charged nutritive proteins and methods
HK1206764A1 (en) Nutritive proteins and methods
IL238095B (en) Proteolytic inactivation of selected proteins in bacterial extraction to improve expression
HK1209413A1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof 5--2-
HRP20190108T1 (hr) Kimerni proteini na bazi hpv/cyaa i njihova upotreba u izazivanju imunosnih odgovora protiv infekcije hpv-om i poremećaja izazvanih hpv-om
HK1204929A1 (en) Timothy grass allergens and methods and uses for immune response modulation
PT2525817T (pt) Vetores de vacina e métodos para o aumento de respostas imunes
EP2804624A4 (de) Impfstoffe gegen antigene im zusammenhang mit therapieresistenz und verwendungsverfahren dafür
HK1208048A1 (en) Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses cyaa
EP3082863A4 (de) Alpha-enolase-spezifische antikörper und verfahren zur verwendung bei immunerkrankungen
EP2892554A4 (de) Hiv-immunstimulierende zusammensetzungen mit rekombinant exprimierten pili auf bakterien und entsprechende verfahren
EP2896294A4 (de) Microrna in menschlicher milch und verwendung davon
EP2814839A4 (de) Antagonisten von bcl-2 und verwendungen davon bei der induktion einer apoptose
EP2930183A4 (de) Rekombinantes protein und verwendungen zur diagnose von multipler sklerose
AU2014318672B2 (en) Recombinant microorganisms and methods of use thereof
EP2920312A4 (de) Onkolytische hsv1-vektoren und verfahren zur verwendung davon
PL2890253T3 (pl) Spożywczy koncentrat w postaci żelu oraz sposób jego wytwarzania
AU2012901301A0 (en) Treatment of inflammatory and immune disorders
IL233882B (en) bcl–2 antagonists and their uses in induction of apoptosis
AP2015008228A0 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230722